サンプル依頼リスト カート
  • English
  • Korean
表紙：放射線毒性治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1345398

放射線毒性治療の世界市場-2023年～2030年

Global Radiation Toxicity Treatment Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.03円
放射線毒性治療の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の放射線毒性治療市場は、2022年に29億米ドルに達し、2023-2030年の予測期間にCAGR 6.1％で成長し、2030年には46億米ドルに達すると予測されています。放射線毒性治療市場は、がん罹患率の増加、高齢化人口の増加、政府の取り組みなどの要因によって牽引されています。電離放射線への被曝による健康への影響は、放射線毒性治療を構成します。治療方法は、放射線被曝の程度、特定の症状、問題の深刻さによって決定されます。

症状を管理し、患者の全般的な健康を維持することが最優先事項です。これには、吐き気、嘔吐、下痢などの懸念事項への対処、疼痛管理、開放創のケアなどが含まれます。介入の効率は、放射線被曝から治療開始までの間隔に影響されることがあります。早期の介入により、いくつかの影響を食い止めたり、軽減したりすることができます。

患者の治療の選択肢は、医療施設、専門療法、薬剤、医療担当者が利用しやすいかどうかに左右されます。放射線感受性は様々な組織や臓器によって異なります。治療計画は、多くの問題のある部位をターゲットとして特別にデザインされます。放射線毒性および関連療法に関する継続的な研究の結果、新たな治療アプローチや介入が開発される可能性があります。

市場力学

がん罹患率の増加が世界の放射線毒性治療市場の成長を牽引しています。

放射線治療の必要性は、世界のがん罹患率の上昇によってもたらされ、それが副作用を管理するための効率的な放射線毒性治療への欲求を支えています。罹患率に変化がなく、人口増加と高齢化が現在の動向をたどった場合、2040年までに年間2,800万人のがん患者が新たに発生すると推定されます。これは2020年から54.9％の増加であり、女児（48.8％）よりも男児（60.6％）の増加が大きくなると予想されています。

アルコール摂取、睡眠不足、喫煙、肥満、高度に加工された食品の摂取はすべて、早期発症がんの潜在的な危険因子でした。驚いたことに、成人の睡眠時間は長年にわたって大きく変化していないにもかかわらず、若者の睡眠時間は数十年前よりはるかに短くなっていることがわかっています。

高齢化人口の増加が世界の放射線毒性治療市場の成長を押し上げる

一般的ながんは、加齢とともに発症する可能性があり、その治療過程で放射線毒性が生じます。調査によると、高齢者（65歳以上と定義される）は若い人よりもがんを発症するリスクが11倍高くなっています。世界人口の高齢化により、高齢者のがん罹患率は今後20年間で増加します。

加齢はがんの危険因子としてよく知られており、がん診断数の増加につながる可能性があります。がんの診断とがんによる死亡の大部分は65歳以上で起こっています。この拡大する公衆衛生の懸念に対して、多くの準備が必要です。高齢のがん患者およびがんサバイバーの要求に徹底したアプローチを提供するためには、この分野でより多くの研究がなされなければなりません。

放射線毒性治療の課題が世界の放射線毒性治療市場の成長を妨げる

患者や医療関係者の間で放射線毒性治療の利点に関する知識が不足していることが、市場の成長を妨げている可能性があります。新しい放射線防護薬や治療法に対する規制当局の承認プロセスには時間と費用がかかるため、市場への革新的なアイテムのイントロダクションが遅れる可能性があります。放射線毒性治療は開発・販売にコストがかかるため、地域や医療システムによっては患者のアクセスが制限される可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • がん罹患率の上昇
    • 抑制要因
      • 放射線毒性治療に伴う課題
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 製品別

  • コロニー刺激因子
  • ヨウ化カリウム
  • プルシアンブルー
  • ジエチレントリアミン五酢酸
  • その他

第10章 適応症別

  • 急性放射線症候群
    • 骨髄症候群
    • 消化器症候群
    • 心血管症候群
  • 慢性放射線症候群

第11章 放射線の種類別

  • 電離放射線
    • アルファ線
    • ベータ線
    • ガンマ線
  • 非電離放射線

第12章 エンドユーザー別

  • 病院
  • 専門クリニック
  • その他

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第14章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第15章 企業プロファイル

  • Amgen
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Jubilant Pharma Limited
  • Tanner Pharma Group
  • Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
  • Recipharm AB
  • Mission Pharmacal Company
  • Partner Therapeutics, Inc.
  • Novartis AG
  • Mylan NV
  • Coherus Biosciences Inc.

第16章 付録

目次
Product Code: PH6762

Overview

The Global Radiation Toxicity Treatment Market reached US$ 2.9 billion in 2022 and is expected to reach US$ 4.6 billion by 2030 growing with a CAGR of 6.1% during the forecast period 2023-2030. The radiation toxicity treatment market is driven by factors such as increasing cancer incidence, rising aging population and government initiatives. The health consequences of exposure to ionizing radiation constitutes radiation toxicity treatment. The method of treatment is determined by the degree of radiation exposure, the particular symptoms, and the seriousness of the problem.

Managing symptoms and preserving the patient's general health are the major priorities. This may involve dealing with concerns including nausea, vomiting, and diarrhea as well as managing pain and taking care of open wounds.The efficiency of interventions can be impacted by the interval between radiation exposure and the start of therapy. Early intervention may stop or lessen some effects.

The treatment options of a patient will be dependent on the accessibility of medical facilities, specialist therapies, drugs, and healthcare personnel. Radiation sensitivity varies among various tissues and organs. Treatment plans will be specifically designed to target the many problematic areas. New therapeutic approaches and interventions may be developed as a result of ongoing study on radiation toxicity and related therapies.

Market Dynamics

The Increasing Cancer Incidence are Driving the Global Radiation Toxicity Treatment Market Growth

The need for radiation therapy is driven by the rising incidence of cancer worldwide, which in turn supports the desire for efficient radiation toxicity treatments to manage the side effects. If incidence stays unchanged and population growth and aging follow current trends, there will be an estimated 28 million new cancer cases annually by 2040. This represents an increase of 54.9% from 2020, and it is anticipated that males will have a greater increase (60.6%) than girls (48.8%).

Alcohol intake, sleep deprivation, smoking, obesity, and consuming highly processed foods were all potential risk factors for early-onset cancer. Surprisingly, researchers discovered that youngsters are getting far less sleep now than they did decades ago, despite the fact that adult sleep length hasn't changed significantly over the years.

The Increasing Aging Population Boost The Global Radiation Toxicity Treatment Market Growth

In population cancer may develop with age and its treatment radiation toxicity comes. According to research, older adults (defined as those 65 and older) had an 11 times higher risk of developing cancer than younger people. The burden of cancer among the elderly will increase during the next 20 years due to the aging of the world population.

Age is a well-known risk factor for cancer, which could lead to an increase in the number of cancer diagnoses. The bulk of cancer diagnoses and cancer deaths occur in people over 65. A lot of preparation is required for this expanding public health concern. To provide a thorough approach to the requirements of elderly cancer patients and survivors, more work must be done in this area.

Challenges with Radiation Toxicity Treatment are Hampering the Global Radiation Toxicity Treatment Market Growth

Growth of the market may be hampered by a lack of knowledge about the advantages of radiation toxicity therapies among patients and medical professionals. The introduction of innovative items to the market may be slowed back by the lengthy and expensive regulatory approvals process for new radioprotective medications and treatments. Radiation toxicity treatments may be expensive to develop and market, which may limit patient access in some areas or within particular healthcare systems.

Segment Analysis

The global radiation toxicity treatment market is segmented based on product, indication, radiation type, end-user and region.

The Acute Radiation Syndrome Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The acute radiation syndrome segment accounted for the highest market stake accounting for approximately 46.2% of the radiation toxicity treatment market in 2022. Cardiovascular illness and cancer frequently co-occur. Cardiovascular toxicities can be caused by chemotherapy, radiation therapy, and other cancer treatments. Coronary artery disease (CAD), valvular heart disease (VHD), heart failure (HF), myocarditis, cardiomyopathies, arrhythmias, and acute and chronic pericardial syndromes may all be brought on by radiation treatment.

Cardiotoxicities brought on by radiation therapy are caused by a variety of processes. The interval between radiation therapy exposure and the onset of cardiac toxicities, as well as the radiation dose to which the heart is exposed, are additional crucial factors. While some cardiac toxicities, such as pericardial effusion or acute pericarditis, arrhythmic events, and conduction abnormalities, can manifest right away after the start of radiotherapies, others, like coronary artery disease, valvular heart disease, chronic pericardial syndromes, and constriction, can take years to manifest.

Geographical Penetration

North America Holds a Dominant Position in the Global Radiation Toxicity Treatment Market

North America is holding around 38.8% of the total market share in 2022. As of October 2022, the acute radiation syndrome (ARS)-related blood cell damage that Nplate from Amgen treats in both children and adults will cost the U.S. Department of Health and Human Services (HHS) an undisclosed amount of money to lock up. When a person's body is subjected to a high dose of penetrating radiation, which is capable of "reaching internal organs in a matter of seconds,", is also known as radiation sickness.

Competitive Landscape

The major global players in the market include: Amgen, Jubilant Pharma Limited, Tanner Pharma Group, Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, Recipharm AB, Mission Pharmacal Company, Partner Therapeutics, Inc., Novartis AG, Mylan NV, and Coherus Biosciences Inc. among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the radiation toxicity treatment market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Resources and attention may be diverted away from research and development projects in the healthcare industry, particularly radiation toxicity therapy, during times of conflict or war.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the radiation toxicity treatment market to improve various aspects of data analysis. Radiomics is the study of quantitative features extracted and analyzed from medical pictures. Based on the particular characteristics of a patient's anatomy, AI-driven radiomics may forecast the likelihood of radiation damage. This knowledge can direct medical decisions and assist practitioners in identifying patients who could be more vulnerable to toxicity.

By Treatment

  • Colony Stimulating Factors
  • Potassium Iodide
  • Prussian Blue
  • Diethylenetriamine Pentaacetic Acid
  • Others

By Indication

  • Acute Radiation Syndrome
    • Bone Marrow Syndrome
    • Gastrointestinal Syndrome
    • Cardiovascular syndrome
  • Chronic Radiation Syndrome

By Radiation Type

  • Ionizing Radiation
    • Alpha Radiation
    • Beta Radiation
    • Gamma Radiation
  • Non-ionizing Radiation

By End-user

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2023, Coherus BioSciences, Inc. reported that The U.S. Food and Drug Administration approved UDENYCA (pegfilgrastim-cbqv), a biosimilar pegfilgrastim that is given the day after chemotherapy to lessen the likelihood of infection as seen by febrile neutropenia. The UDENYCA autoinjector has a simple, user-friendly design that makes it suitable for usage in both in-office and at-home care settings. It is indicated to patients who receive radiation doses that are myelosuppressive in nature are more likely to survive (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Why Purchase the Report?

  • To visualize the global radiation toxicity treatment market segmentation based on the product, indication, radiation type, end-user and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of radiation toxicity treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of critical products of all the major players.

The global radiation toxicity treatment market report would provide approximately 69 tables, 69 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Radiation Type
  • 3.4. Snippet by End-user
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising cancer incidence
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges associated with radiation toxicity treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Product

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.1.2. Market Attractiveness Index, By Product
  • 9.2. Colony Stimulating Factors*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Potassium Iodide
  • 9.4. Prussian Blue
  • 9.5. Diethylenetriamine Pentaacetic Acid
  • 9.6. Others

10. By Indication

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.1.2. Market Attractiveness Index, By Indication
  • 10.2. Acute Radiation Syndrome*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 10.2.3. Bone Marrow Syndrome
    • 10.2.4. Gastrointestinal Syndrome
    • 10.2.5. Cardiovascular syndrome
  • 10.3. Chronic Radiation Syndrome

11. By Radiation Type

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
    • 11.1.2. Market Attractiveness Index, By Radiation Type
    • 11.1.3. Ionizing Radiation*
    • 11.1.4. Introduction
    • 11.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 11.1.5.1. Alpha Radiation
      • 11.1.5.2. Beta Radiation
      • 11.1.5.3. Gamma Radiation
    • 11.1.6. Non-ionizing Radiation

12. By End-user

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.1.2. Market Attractiveness Index, By End-user
    • 12.1.3. Hospitals*
      • 12.1.3.1. Introduction
      • 12.1.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 12.1.4. Specialty Clinics
    • 12.1.5. Others

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radiation Type
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. ProductBenchmarking
  • 14.3. Company Share Analysis
  • 14.4. Key Developments and Strategies

15. Company Profiles

  • 15.1. Amgen*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Jubilant Pharma Limited
  • 15.3. Tanner Pharma Group
  • 15.4. Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
  • 15.5. Recipharm AB
  • 15.6. Mission Pharmacal Company
  • 15.7. Partner Therapeutics, Inc.
  • 15.8. Novartis AG
  • 15.9. Mylan NV
  • 15.10. Coherus Biosciences Inc.

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us